|Articles|September 25, 2016
Tufts CSDD Releases Findings from Diabetes Study
September 26, 2016
Advertisement
According to results of a new study by the Tufts Center for the Study of Drug Development, the development process for new diabetes and non-diabetes endocrine drugs is riskier compared to all drug development. The study examined the development pathways and characteristics of 27 diabetes and 34 non-diabetes endocrine drugs.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline
2
What the Peptide Advisory Vote Actually Means: Q&A with James LaValle
3
Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321
4
M&A Roundup: IntraGel & UroGen Sign Collaboration & Investment Agreements, Lupin & Tenpoint Form Commercialization Collaboration
5